Tags

Type your tag names separated by a space and hit enter

[Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
Zhonghua Xue Ye Xue Za Zhi. 2005 Jun; 26(6):327-31.ZX

Abstract

OBJECTIVE

To evaluate the method and value of detecting bone marrow minimal residual disease (MRD) in B lineage acute lymphoblastic leukemia (B-ALL) by multiparameter flow cytometry (FCM).

METHODS

The FCM immunophenotyping of B-lymphocyte precursors in regenerating stage and MRD was analyzed by using two sets of 4-color antibody panels, including mainly CD34, CD10, CD45, CD19, in 26 regenerating bone marrow samples after chemotherapy and 297 consecutive bone marrow specimens from 50 patients with B-ALL, respectively. The immunophenotype of leukemia cells of B-ALL was also detected by four to six antibodies combination of 4-color CD45/SSC gating FCM. The CD19, CD10, CD34 fluorescence intensity of B-cell precursors in normal and leukemic bone marrow was compared by relatively quantitative method.

RESULTS

Twelve patients were MRD positive (MRD(+)) among 50 patients during MRD monitoring, the percentages of residual leukemia cells were 0.06% to 7.73%. Eleven cases displayed CD45, CD34, CD19, CD10 antigens aberrant expression. Five patients were bone marrow relapsed and 4 of them were MRD (+) 7-17 weeks before relapse. The percentages of leukemia cells in all the 4 patients were over 0.1%. Only one patient relapsed with MRD negative. The regenerated B precursors could be divided into 3 stages according to the expression of CD45, CD34, CD19, CD10, CD22, and CD20 antigens. Abnormal expression of CD45, CD34, CD19, and CD10 were detected in 71.8% of 213 patients with B-ALL, the percentage of only aberrant expression of CD38 and myeloid antigen was 8.1%.

CONCLUSION

Detection of MRD by multiparameter flow cytometry is a rapid, quantitative and sensitive approach, and has a higher predictability for relapse.

Authors+Show Affiliations

Institute of Hematology, People's Hospital of Peking University, Beijing 100044, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

chi

PubMed ID

16185473

Citation

Liu, Yan-rong, et al. "[Detection of Minimal Residual Disease in B Lineage Acute Lymphoblastic Leukemia By 4-color Flow Cytometry]." Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, vol. 26, no. 6, 2005, pp. 327-31.
Liu YR, Wang H, Chang Y, et al. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry]. Zhonghua Xue Ye Xue Za Zhi. 2005;26(6):327-31.
Liu, Y. R., Wang, H., Chang, Y., Cheng, Y. F., Fu, J. Y., Zhang, L. P., Liu, G. L., & Chen, S. S. (2005). [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry]. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 26(6), 327-31.
Liu YR, et al. [Detection of Minimal Residual Disease in B Lineage Acute Lymphoblastic Leukemia By 4-color Flow Cytometry]. Zhonghua Xue Ye Xue Za Zhi. 2005;26(6):327-31. PubMed PMID: 16185473.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry]. AU - Liu,Yan-rong, AU - Wang,Hui, AU - Chang,Yan, AU - Cheng,Yi-fei, AU - Fu,Jia-yu, AU - Zhang,Le-ping, AU - Liu,Gui-lan, AU - Chen,Shan-shan, PY - 2005/9/28/pubmed PY - 2009/5/8/medline PY - 2005/9/28/entrez SP - 327 EP - 31 JF - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi JO - Zhonghua Xue Ye Xue Za Zhi VL - 26 IS - 6 N2 - OBJECTIVE: To evaluate the method and value of detecting bone marrow minimal residual disease (MRD) in B lineage acute lymphoblastic leukemia (B-ALL) by multiparameter flow cytometry (FCM). METHODS: The FCM immunophenotyping of B-lymphocyte precursors in regenerating stage and MRD was analyzed by using two sets of 4-color antibody panels, including mainly CD34, CD10, CD45, CD19, in 26 regenerating bone marrow samples after chemotherapy and 297 consecutive bone marrow specimens from 50 patients with B-ALL, respectively. The immunophenotype of leukemia cells of B-ALL was also detected by four to six antibodies combination of 4-color CD45/SSC gating FCM. The CD19, CD10, CD34 fluorescence intensity of B-cell precursors in normal and leukemic bone marrow was compared by relatively quantitative method. RESULTS: Twelve patients were MRD positive (MRD(+)) among 50 patients during MRD monitoring, the percentages of residual leukemia cells were 0.06% to 7.73%. Eleven cases displayed CD45, CD34, CD19, CD10 antigens aberrant expression. Five patients were bone marrow relapsed and 4 of them were MRD (+) 7-17 weeks before relapse. The percentages of leukemia cells in all the 4 patients were over 0.1%. Only one patient relapsed with MRD negative. The regenerated B precursors could be divided into 3 stages according to the expression of CD45, CD34, CD19, CD10, CD22, and CD20 antigens. Abnormal expression of CD45, CD34, CD19, and CD10 were detected in 71.8% of 213 patients with B-ALL, the percentage of only aberrant expression of CD38 and myeloid antigen was 8.1%. CONCLUSION: Detection of MRD by multiparameter flow cytometry is a rapid, quantitative and sensitive approach, and has a higher predictability for relapse. SN - 0253-2727 UR - https://www.unboundmedicine.com/medline/citation/16185473/[Detection_of_minimal_residual_disease_in_B_lineage_acute_lymphoblastic_leukemia_by_4_color_flow_cytometry]_ L2 - http://journal.yiigle.com/LinkIn.do?linkin_type=pubmed&issn=0253-2727&year=2005&vol=26&issue=6&fpage=327 DB - PRIME DP - Unbound Medicine ER -